ThomasJHarringtonMD

Oncology • Miami, FL

Assistant Professor of Medical Oncology, University Miami School of Medicine

Join to view full profile

Dr. Harrington is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harrington's full profile

Already have an account?

Office
1611 NW 12th Ave
# M851
Miami, FL 33136
Phone+1 305-585-1111

Fax+1 305-243-8470

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1991 - 1992
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1985 - 1988
University of Miami Leonard M. Miller School of MedicineClass of 1985

Certifications & Licensure

FL State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Start of enrollment: 2009 Apr 21
Terminated
Phase 2

Publications & Presentations

PubMed

1 citations
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi-center analysis of 719 disease ...
Jeremy W Jacobs, Caroline G Stanek, Garrett S Booth, Argiris Symeonidis, Andrew W Shih
American Journal of Hematology. 2024-11-01
3 citations
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Mark T Gladwin, Victor R Gordeuk, Payal C Desai, Caterina Minniti, Enrico M Novelli
The Lancet. Haematology. 2024-05-01
7 citations
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington
Blood. 2024-02-29

Abstracts/Posters

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...
Thomas J. Harrington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Other Languages

Spanish